Healthcare

Healthcare sector stocks including pharmaceuticals, biotechnology, and medical devices.

61 articles

Healthcare | SRPT | 8h ago

Sarepta Therapeutics: Price Target Cut Signals Shift Ahead

Sarepta Therapeutics sees its price target reduced to $38 by Wells Fargo, while still holding an Overweight rating. What does this mean for SRPT investors?

Healthcare | ZTS | 9h ago

Zoetis Inc. Expands Market Presence Amid Strong MFA Integration

ZTS is gaining traction as Phibro highlights strong fiscal results and MFA integration from Zoetis, signaling a solid growth trajectory ahead.

Healthcare | HUM | 21h ago

Humana Inc. Advances on Strategic MaxHealth Acquisition

Humana Inc. is focusing on expanding its senior care footprint with the acquisition of MaxHealth. This strategic move could change HUM's future.

Healthcare | HIMS | 39h ago

Behind HIMS's Big Move: Surprising Growth Potential Beyond GLP-1 Drugs

HIMS shows surprising growth potential that may not rely on GLP-1 drugs, indicating a promising trajectory for investors.

Healthcare | LLY | 40h ago

Health Care Rally Sends Eli Lilly Shares Higher

A recent surge in health care stocks has propelled LLY shares upward, reflecting investor optimism about Eli Lilly's future in the industry.

Healthcare | PODD | 43h ago

Insulet Corp.: Price Target Trim Signals Cautious Optimism for PODD

PODD’s fair value has been adjusted to $354.40, indicating a cautious yet optimistic outlook. Explore the key drivers behind this shift.

Healthcare | REGN | 43h ago

Regeneron Pharmaceuticals Drops as FDA Approval for Dupixent Weighs on Shares

REGN faces mixed market reactions post-FDA approval of Dupixent. Understanding this event's implications is crucial for investors considering REGN.

Healthcare | GILD | 2d ago

GILD: How Q4 Earnings Reveal Growth Opportunities

GILD's Q4 earnings report unveils significant growth potential. Learn how Gilead Sciences is positioning itself for future success.

Healthcare | TFX | 2d ago

Teleflex Inc. Posts $714.3M Loss as Market Eyes Q4 Earnings Fallout

Teleflex Inc. reported a significant loss of $714.3 million for Q4, raising critical concerns about TFX's financial trajectory.

Healthcare | BMY | 3d ago

BMY Bucks the Trend as NYSE Pre-Market Update Surfaces

BMY remains resilient despite market fluctuations following the latest NYSE pre-market update spelling potential opportunities for investors.

Healthcare | ELV | 3d ago

Elevance Health's Leadership Change Becomes Key Catalyst for ELV

Elevance Health's latest leadership change under Ratnakar Lavu is set to enhance customer experience, impacting ELV's growth trajectory.

Healthcare | ALNY | 4d ago

Behind ALNY's Big Move: Frontier Pact Adds Genetic Drug Optionality

ALNY has announced a pivotal partnership with Frontier Pact, enhancing its genetic drug offerings. This could significantly impact ALNY's market trajectory.

Healthcare | ABT | 4d ago